TetraLogic Pharmaceuticals Corp
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to… Read more
TetraLogic Pharmaceuticals Corp (TLOG) - Total Liabilities
Latest total liabilities as of September 2016: $73.73 Million USD
Based on the latest financial reports, TetraLogic Pharmaceuticals Corp (TLOG) has total liabilities worth $73.73 Million USD as of September 2016.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
TetraLogic Pharmaceuticals Corp - Total Liabilities Trend (2011–2015)
This chart illustrates how TetraLogic Pharmaceuticals Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
TetraLogic Pharmaceuticals Corp Competitors by Total Liabilities
The table below lists competitors of TetraLogic Pharmaceuticals Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ebiquity Plc
LSE:EBQ
|
UK | GBX46.12 Million |
|
LINDSAY AUSTRALIA
BE:J3B
|
Germany | €400.69 Million |
|
Armstrong Flooring Inc
OTCMKTS:AFIIQ
|
USA | $317.80 Million |
|
PRIMAG (P9R.SG)
STU:P9R
|
Germany | €2.12 Million |
|
ELEMENTOS (9EM.SG)
STU:9EM
|
Germany | €1.98 Million |
|
CANFOR PULP (8CP.SG)
STU:8CP
|
Germany | €297.20 Million |
|
PaxMedica, Inc. Common Stock
PINK:PXMD
|
USA | $2.75 Million |
Liability Composition Analysis (2011–2015)
This chart breaks down TetraLogic Pharmaceuticals Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TetraLogic Pharmaceuticals Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TetraLogic Pharmaceuticals Corp (2011–2015)
The table below shows the annual total liabilities of TetraLogic Pharmaceuticals Corp from 2011 to 2015.
| Year | Total Liabilities | Change |
|---|---|---|
| 2015-12-31 | $69.96 Million | -17.58% |
| 2014-12-31 | $84.89 Million | +1613.76% |
| 2013-12-31 | $4.95 Million | -93.24% |
| 2012-12-31 | $73.32 Million | +6.36% |
| 2011-12-31 | $68.94 Million | -- |